A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2011
09/29/2011	US20110237577 Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases
09/29/2011	US20110237576 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having bace1-inhibiting activity
09/29/2011	US20110237575 Inhibitors of fatty acid binding protein (fabp)
09/29/2011	US20110237574 Use of modified pyrimidine compounds to promote stem cell migration and proliferation
09/29/2011	US20110237573 N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators
09/29/2011	US20110237572 Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
09/29/2011	US20110237571 Phthalazine derivatives
09/29/2011	US20110237570 Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
09/29/2011	US20110237569 SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS
09/29/2011	US20110237568 Crystalline forms
09/29/2011	US20110237567 Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
09/29/2011	US20110237566 Therapeutic Macrolide Compounds and Their Use
09/29/2011	US20110237565 Heterocyclic inhibitors of histamine receptors for the treatment of disease
09/29/2011	US20110237564 Imidazopyrimidine derivatives
09/29/2011	US20110237563 Fast dissolving drug delivery systems
09/29/2011	US20110237562 Use of a container of an inorganic additive containing plastic material
09/29/2011	US20110237561 Organic compounds
09/29/2011	US20110237560 Modulating and/or detecting activation induced deaminase and methods of use thereof
09/29/2011	US20110237559 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1
09/29/2011	US20110237558 Stabilized composition for treating psoriasis
09/29/2011	US20110237557 Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
09/29/2011	US20110237556 (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-HYDROXYVITAMIN D3
09/29/2011	US20110237555 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea
09/29/2011	US20110237554 Combination therapies: inhibitors of GABA transaminase and NKCC1
09/29/2011	US20110237553 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
09/29/2011	US20110237552 Composite Material Consisting of a Collagen Matrix Mineralised with Silicate and Calcium Phosphate Phases, Method for the Production and Use Thereof
09/29/2011	US20110237551 Para-Coumaric Acid or Para-Hydroxycinnamic Acid Derivatives and Their Use in Cosmetic or Dermatological Compositions
09/29/2011	US20110237550 5-azaindole bisphosphonates
09/29/2011	US20110237548 Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
09/29/2011	US20110237547 Pharmaceutical compositions for the treatment of fungal infections
09/29/2011	US20110237546 Method for treating a mammal by administration of a compound having the ability to release co
09/29/2011	US20110237545 Trihydroxy polyunsaturated eicosanoid derivatives
09/29/2011	US20110237544 Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use
09/29/2011	US20110237543 Composition for Prevention or Treatment of Eye Diseases
09/29/2011	US20110237542 Composition for preventing adhesion
09/29/2011	US20110237541 Transdermally administered aliskiren
09/29/2011	US20110237540 Cyclodextrin-based polymers for therapeutic delivery
09/29/2011	US20110237539 Spinning Solution and Method for Manufacturing Biomaterial Fibers
09/29/2011	US20110237538 Treatment of lysosomal storage disorders and other proteostatic diseases
09/29/2011	US20110237537 Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
09/29/2011	US20110237536 Treating or Preventing Pain Using Spicamycin Derivatives
09/29/2011	US20110237535 Use of Induced Pluripotent Cells and other Cells for Screening Compound Libraries
09/29/2011	US20110237534 Methods for treating gastrointestinal diseases
09/29/2011	US20110237533 Novel polyphenol compound
09/29/2011	US20110237532 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
09/29/2011	US20110237531 Method for producing sophorose lipid
09/29/2011	US20110237530 Anti-xdr-tb drug, anti-mdr-tb drug, and combination anti-tuberculosis drug
09/29/2011	US20110237529 Adenosine Analogs and Their Use
09/29/2011	US20110237528 Compositions and methods comprising imidazole and triazole derivatives
09/29/2011	US20110237527 Sglt-2 inhibitors, methods of making them, and uses thereof
09/29/2011	US20110237526 Method for the preparation of a crystalline form
09/29/2011	US20110237525 Method of ameliorating oxidative stress and supplementing the diet
09/29/2011	US20110237522 Neutral nanotransporters
09/29/2011	US20110237521 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
09/29/2011	US20110237518 Method for treating or preventing bladder cancer using the depdc1 polypeptide
09/29/2011	US20110237514 PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING Frizzled1, Frizzled2 OR Frizzled7 EXTRACELLULAR CYSTEINE-RICH DOMAIN
09/29/2011	US20110237512 Methods for Treating Bleeding Disorders Using Sulfated Polysaccharides
09/29/2011	US20110237511 EP4 Receptor Agonist, Compositions and Methods Thereof
09/29/2011	US20110237505 Compositions and Methods for Treating Obesity and Diabetes
09/29/2011	US20110237504 Delivery agents for enhancing mucosal absorption of therapeutic agents
09/29/2011	US20110237497 Compositions of a v-atpase inhibitor in combination with a glucocorticoid receptor ligand and methods of use
09/29/2011	US20110237495 Functional metabolomics coupled microfluidic chemotaxis device and identification of novel cell mediators
09/29/2011	US20110237435 Lipophilic nucleic acid delivery vehicle and methods of use thereof
09/29/2011	US20110236510 Pregnane glycoside compositions and caralluma extract products and uses thereof
09/29/2011	US20110236508 L-arginine-based formulation for oral absorption
09/29/2011	US20110236507 Inhibition of dna polymerases to augment chemotherapeutic and antimicrobial agents
09/29/2011	US20110236506 Pharmaceutical association containing lipoic acid and hydroxycitric acid as active ingredients
09/29/2011	US20110236505 Carbohydrate bar
09/29/2011	US20110236502 Vitamin Strip (V1)
09/29/2011	US20110236501 Injectable dual delivery allograph bone/polymer composite for treatment of open fractures
09/29/2011	US20110236495 Anti-cancer nanoparticle compositions and methods of use
09/29/2011	US20110236494 Ciprofloxacin oral suspension
09/29/2011	US20110236492 Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives
09/29/2011	US20110236487 Solid ganaxolone formulations and methods for the making and use thereof
09/29/2011	US20110236486 Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels thereof
09/29/2011	US20110236485 Shell and core dosage form approaching zero-order drug release
09/29/2011	US20110236483 Rna vector therapy
09/29/2011	US20110236480 Prebiotic formulations and methods of use
09/29/2011	US20110236479 Direct compression formulation and process
09/29/2011	US20110236478 Co-crystals and pharmaceutical formulations comprising the same
09/29/2011	US20110236477 Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
09/29/2011	US20110236476 Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
09/29/2011	US20110236475 Granular pharmaceutical compositions
09/29/2011	US20110236474 Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration
09/29/2011	US20110236473 Stable aliskiren formulations
09/29/2011	US20110236472 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
09/29/2011	US20110236471 Platinum complexes and methods for inhibiting tumor cell proliferation
09/29/2011	US20110236466 Chemo vector therapy to deliver chemotherapy molecules to specific cells to manage breast cancer, other cancers and inflammatory disorders
09/29/2011	US20110236463 Formulations for systemic buccal delivery comprising s-adenosylmethionine, their preparation and use
09/29/2011	US20110236462 Intravaginal drug delivery device
09/29/2011	US20110236461 Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor
09/29/2011	US20110236460 Therapeutic Implant
09/29/2011	US20110236459 Therapeutic Implant
09/29/2011	US20110236454 Injectable drug delivery formulation
09/29/2011	US20110236439 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
09/29/2011	US20110236437 Nanoparticles and methods of use
09/29/2011	US20110236436 Pharmaceutical composition for modified release
09/29/2011	US20110236434 Polymorphic Forms of ST-246 and Methods of Preparation
09/29/2011	US20110236433 Wound care device
09/29/2011	US20110236419 Recombinant cdv compositions and uses thereof

1 ... 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 ... 7860